Rivory L P, Findlay M, Clarke S, Bishop J
Medical Oncology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
J Chromatogr B Biomed Sci Appl. 1998 Sep 4;714(2):355-9. doi: 10.1016/s0378-4347(98)00216-3.
A reversed-phase high-performance liquid chromatographic method with fluorescence detection was developed and validated for the quantitation of SN-38, the active metabolite of irinotecan (CPT-11), a new anticancer drug. This method uses solid-phase extraction with a C18 column for sample clean-up and concentration following acidification of human plasma with two volumes of 0.1 M HCl. Using blank plasma spiked with SN-38, we found the assay to be linear over the concentration range of 10-500 pM (3.9-195 pg/ml) with acceptable total and within-day imprecision. The recovery of SN-38 ranged from 48.3% (10 pM) to 91.5% (500 pM) whereas that of the internal standard, 20-(S)-camptothecin, was 96.9% (500 pM). This method represents a sizeable increase in sensitivity over other published methods and is shown to be suitable for the measurement of 'trough' concentrations of SN-38 during the treatment of patients with a weekly regimen of irinotecan.
开发并验证了一种采用荧光检测的反相高效液相色谱法,用于定量测定新型抗癌药物伊立替康(CPT - 11)的活性代谢物SN - 38。该方法采用C18柱进行固相萃取,在用人血浆加两倍体积的0.1 M HCl酸化后进行样品净化和浓缩。使用加有SN - 38的空白血浆,我们发现该测定法在10 - 500 pM(3.9 - 195 pg/ml)的浓度范围内呈线性,总不精密度和日内不精密度均可接受。SN - 38的回收率在48.3%(10 pM)至91.5%(500 pM)之间,而内标20 -(S)-喜树碱的回收率为96.9%(500 pM)。与其他已发表的方法相比,该方法的灵敏度有显著提高,并且已证明适用于在每周使用伊立替康治疗方案的患者中测量SN - 38的“谷”浓度。